NL300834I2 - - Google Patents

Info

Publication number
NL300834I2
NL300834I2 NL300834C NL300834C NL300834I2 NL 300834 I2 NL300834 I2 NL 300834I2 NL 300834 C NL300834 C NL 300834C NL 300834 C NL300834 C NL 300834C NL 300834 I2 NL300834 I2 NL 300834I2
Authority
NL
Netherlands
Application number
NL300834C
Other languages
Dutch (nl)
Original Assignee
The Medicines Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41722337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300834(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Medicines Co filed Critical The Medicines Co
Publication of NL300834I2 publication Critical patent/NL300834I2/nl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NL300834C 2008-08-30 2016-10-11 NL300834I2 (https=)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9331408P 2008-08-30 2008-08-30
US9349708P 2008-09-02 2008-09-02
PCT/US2009/055466 WO2010025438A2 (en) 2008-08-30 2009-08-29 Methods of treatment using single doses of oritavancin

Publications (1)

Publication Number Publication Date
NL300834I2 true NL300834I2 (https=) 2016-11-16

Family

ID=41722337

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300834C NL300834I2 (https=) 2008-08-30 2016-10-11

Country Status (18)

Country Link
US (2) US8420592B2 (https=)
EP (3) EP3006038B1 (https=)
JP (1) JP5782615B2 (https=)
CN (2) CN102215858A (https=)
AU (1) AU2009285564B2 (https=)
CA (1) CA2736860C (https=)
DK (2) DK3006038T3 (https=)
EA (1) EA020490B1 (https=)
ES (2) ES2570401T3 (https=)
FI (1) FI3006038T3 (https=)
HU (3) HUE027373T2 (https=)
MX (1) MX2011002249A (https=)
NL (1) NL300834I2 (https=)
NO (1) NO2016019I2 (https=)
NZ (1) NZ591525A (https=)
PL (2) PL2337575T3 (https=)
PT (1) PT3006038T (https=)
WO (1) WO2010025438A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3006038T (pt) 2008-08-30 2024-08-23 The Medicines Co Doses únicas de oritavancina para tratamento ou prevenção de uma infeção bacteriana
AU2010245097B2 (en) 2009-04-28 2015-08-13 Melinta Therapeutics, Inc. Methods of treating bacterial infections using oritavancin
WO2014031681A1 (en) * 2012-08-20 2014-02-27 The University Of Chicago Inhibiting gram positive bacteria
US20160101148A1 (en) * 2013-04-22 2016-04-14 The Medicines Company Treatment and prevention of bacterial skin infections using oritavancin
LT3038616T (lt) * 2013-08-26 2023-05-25 Melinta Therapeutics, Inc. Bakteriemijos ir osteomielito gydymo būdai naudojant oritavanciną
WO2015031579A2 (en) * 2013-08-28 2015-03-05 The Medicines Company Methods for treating bacterial infections using oritavancin and polymyxins
US20170119793A1 (en) * 2014-06-12 2017-05-04 Cem-102 Pharmaceuticals, Inc. Compositions and methods for treating bone and joint infections
EP4509178A3 (en) * 2014-07-17 2025-06-25 Melinta Therapeutics, LLC High purity oritavancin and method of producing same
RU2018129076A (ru) * 2016-02-18 2020-03-18 Мелинта Терапьютикс, Инк. Составы оритаванцина
WO2017179003A1 (en) * 2016-04-15 2017-10-19 Lupin Limited Topical compositions for ophthalmic and otic use
CN108409837B (zh) 2018-03-06 2021-09-24 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
US5994297A (en) * 1997-08-22 1999-11-30 Eli Lilly And Company Therapy for Staphylococcus aureus
BR0010244A (pt) * 1999-05-03 2002-01-08 Lilly Co Eli Doses mensais para tratamento de infecções por streptococcus pneumoniae
JP4870314B2 (ja) 2000-05-02 2012-02-08 セラヴァンス, インコーポレーテッド シクロデキストリンを含むグリコペプチド抗生物質組成物
US20030176327A1 (en) * 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
WO2003102134A2 (en) * 2002-05-28 2003-12-11 Becton, Dickinson And Company Pancreatic acinar cells into insulin producing cells
AU2003274927A1 (en) * 2002-08-23 2004-03-11 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US20040127403A1 (en) * 2002-09-06 2004-07-01 Francesco Parenti Methods for treating and preventing Gram-positive bacteremias
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
ES2445941T3 (es) * 2006-09-25 2014-03-06 The Medicines Company Uso de oritavancina para la prevención y el tratamiento del ántrax
PT3006038T (pt) 2008-08-30 2024-08-23 The Medicines Co Doses únicas de oritavancina para tratamento ou prevenção de uma infeção bacteriana
AU2010245097B2 (en) * 2009-04-28 2015-08-13 Melinta Therapeutics, Inc. Methods of treating bacterial infections using oritavancin
WO2015031579A2 (en) * 2013-08-28 2015-03-05 The Medicines Company Methods for treating bacterial infections using oritavancin and polymyxins

Also Published As

Publication number Publication date
HUE027373T2 (hu) 2016-09-28
DK2337575T3 (en) 2016-05-23
EP4464375A2 (en) 2024-11-20
JP2012501349A (ja) 2012-01-19
HUE068423T2 (hu) 2024-12-28
EA020490B1 (ru) 2014-11-28
EP2337575B1 (en) 2016-04-13
EP2337575A4 (en) 2012-10-17
ES2570401T3 (es) 2016-05-18
EP2337575A1 (en) 2011-06-29
NZ591525A (en) 2014-03-28
CA2736860C (en) 2020-04-28
HUS1600039I1 (hu) 2016-11-28
EP3006038B1 (en) 2024-07-03
PL2337575T3 (pl) 2016-09-30
DK3006038T3 (da) 2024-08-26
FI3006038T3 (fi) 2024-08-12
PT3006038T (pt) 2024-08-23
AU2009285564A1 (en) 2010-03-04
US8420592B2 (en) 2013-04-16
MX2011002249A (es) 2011-06-24
PL3006038T3 (pl) 2024-11-12
US12514899B2 (en) 2026-01-06
EP3006038A1 (en) 2016-04-13
US20130172237A1 (en) 2013-07-04
CA2736860A1 (en) 2010-03-04
AU2009285564B2 (en) 2014-05-22
WO2010025438A9 (en) 2010-05-14
CN102215858A (zh) 2011-10-12
WO2010025438A2 (en) 2010-03-04
NO2016019I1 (no) 2016-10-11
CN106620649A (zh) 2017-05-10
ES2994966T3 (en) 2025-02-04
NO2016019I2 (no) 2019-01-25
EP4464375A3 (en) 2025-02-26
US20110201546A1 (en) 2011-08-18
EA201100413A1 (ru) 2012-01-30
JP5782615B2 (ja) 2015-09-24

Similar Documents

Publication Publication Date Title
BR112016019572A2 (https=)
BRPI0909040A2 (https=)
BRPI0917573A2 (https=)
BRPI0908549B8 (https=)
BRPI0918697A2 (https=)
BRPI0917525A2 (https=)
BRPI0920750A2 (https=)
BRPI0919470A2 (https=)
BRPI0907698A2 (https=)
BRPI0917618A8 (https=)
BRPI0922455A2 (https=)
BRPI0923734A2 (https=)
BRPI0912727A2 (https=)
BRPI0922669A2 (https=)
BRPI0908285A2 (https=)
BRPI0910485A2 (https=)
BRPI0914750A2 (https=)
BRPI0919811A2 (https=)
BRPI0915616A2 (https=)
BRPI0908120A2 (https=)
BRPI0904541A8 (https=)
BRPI0912462A2 (https=)
BRPI0920914A2 (https=)
BRPI0922550A2 (https=)
BRPI0916284A2 (https=)